Tuesday - April 21, 2026

Category Archives: Marketing & Sales

CROLabs Launches AI-Powered A/B Testing Platform to Automate Conversion Optimization

AI-powered A/B testing platform dashboard illustrating conversion rate optimization and data-driven experimentation. CROLabs has launched an AI-powered A/B testing tool designed to simplify and accelerate conversion rate optimization. The platform combines automation and data-driven insights to help teams analyze, test, … Continue reading →

Multiple Sclerosis Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharma, Sanofi, RemeGen

The Key Multiple Sclerosis Companies in the market include – Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others.   DelveInsight’s … Continue reading →

Amyotrophic Lateral Sclerosis Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | COSCIENS Biopharma, BenevolentAI, Verge Genomics, ProJenX, QurAlis Crp.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Amyotrophic Lateral Sclerosis pipeline constitutes 70+ key companies continuously working towards developing 80+ Amyotrophic Lateral Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Primary Biliary Cholangitis Pipeline Set for Major Breakthroughs by 2026 with 25+ Therapies and Strong Clinical Momentum from GlaxoSmithKline, Novartis, and CymaBay Therapeutics | DelveInsight

Primary Biliary Cholangitis Pipeline Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, Calliditas Therapeutics, Hepagene, Calliditas Therapeutics, Dr Falk Pharma, Mirum Pharmaceuticals, GlaxoSmithKline, and others DelveInsight’s, “Primary … Continue reading →